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Abstract
Background: Screening tests for cervical cancer are effective in reducing the disease burden. In Thailand, a Pap
smear program has been implemented throughout the country for 40 years. In 2008 the Ministry of Public Health
(MoPH) unexpectedly decided to scale up the coverage of free cervical cancer screening services, to meet an
ambitious target. This study analyzes the processes and factors that drove this policy innovation in the area of
cervical cancer control in Thailand.
Methods: In-depth interviews with key policy actors and review of relevant documents were conducted in 2009.
Data analysis was guided by a framework, developed on public policy models and existing literature on scaling-up
health care interventions.
Results: Between 2006 and 2008 international organizations and the vaccine industry advocated the introduction
of Human Papillomavirus (HPV) vaccine for the primary prevention of cervical cancer. Meanwhile, a local study
suggested that the vaccine was considerably less cost-effective than cervical cancer screening in the Thai context.
Then, from August to December 2008, the MoPH carried out a campaign to expand the coverage of its cervical
cancer screening program, targeting one million women. The study reveals that several factors were influential in
focusing the attention of policymakers on strengthening the screening services. These included the high burden
of cervical cancer in Thailand, the launch of the HPV vaccine onto the global and domestic markets, the country’s
political instability, and the dissemination of scientific evidence regarding the appropriateness of different options
for cervical cancer prevention. Influenced by the country’s political crisis, the MoPH’s campaign was devised in a
very short time. In the view of the responsible health officials, the campaign was not successful and indeed, did
not achieve its ambitious target.
Conclusion: The Thai case study suggests that the political crisis was a crucial factor that drew the attention of
policymakers to the cervical cancer problem and led the government to adopt a policy of expanding coverage of
screening services. At the same time, the instability in the political system impeded the scaling up process, as it
constrained the formulation and implementation of the policy in the later phase.
Background
Cervical cancer is the second most common cancer in
women worldwide [1]. In particular, it is a major cause
of deaths in developing countries. The development of
this cancer is associated with the infection of some
strains of human papillomavirus (HPV) [2]. The disease
is preventable through screening tests such as Pap
smears, visual inspections with acetic acid (VIA) and
HPV DNA test. While such secondary preventive
approaches are notably effective in reducing the burden
of cervical cancer in industrialized societies, the disease
remains an important public health problem in poor set-
tings because of the inadequate coverage and quality of
screening services [3,4]. In Thailand, a campaign to
enhance uptake of the government’s cervical cancer
screening program was carried out over a three-month
period in 2008. Difficulties were found, however, with
gaining access to the large target group. This paper
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radical shift, and other developments, in the Thai policy.
Pap smear is a technique that gathers cells from the
cervix to be examined for abnormalities. This cytology-
based test is resource intensive as it requires a well-
established infrastructure, including laboratories and
well-trained health workers [3]. In many developing
countries, the lack of personnel and necessary equip-
ment are critical constraints to screening test provision
[5]. In contrast, VIA is a naked-eye screening tool for
the detection of precancerous tissue after the application
of dilute acetic acid to the uterus cervix. Since 2005 this
approach followed by immediate cryotherapy, the expo-
sure of tissues to extreme cold to eliminate abnormal
cells, has been recommended for use in low-resource
settings where it is difficult to introduce Pap smears and
other advanced technologies [3]. Apart from supply-side
financial and technical limitations, multiple visits for
testing, gaining access to results and subsequent treat-
ment are crucial hurdles for effective screening, espe-
cially among people living in remote areas [6]. In some
areas, inaccurate beliefs and poor knowledge of the dis-
ease among the target population are key factors imped-
ing the coverage of cervical cancer screening [7].
Like other countries in the developing world, cervical
cancer is a disease of high burden in Thailand, with an
incidence of 20 to 25 per 100,000 female population
during the past two decades [8]. The cancer is prevalent
in middle-aged and older women, with approximately
2,600 women reported to die of cervical cancer every
year. Pap smear tests for early detection of pre-cancer-
ous cells have been available in health facilities through-
out the country for 40 years, under the supervision of
the Ministry of Public Health (MoPH)’s Department of
Medical Services [9]. In addition, in 2000 VIA and
cryotherapy were introduced in some areas. Coming
under the responsibility of the MoPH’s Department of
Health, this single-visit approach is, however, only avail-
able in 16 out of 76 provinces and has a history of slow
expansion [10]. Both screening tests are financed by the
National Health Security Office (NHSO) – the managing
agency for the Universal Health Coverage (UC) plan.
Despite the long-time availability of cervical cancer
screening tests in Thailand, the services have not signifi-
cantly contributed to a health impact in the country.
A study suggests that coverage with Pap smears and
VIA was as low as 11% and 8%, respectively, of the
defined target population in 2005 [11]. With regard to
Pap smear provision, quality problems such as mis-
matches between slides and names of clients, delays in
delivering test results and loss to follow-up was evident.
The lack of public awareness and knowledge of cervical
cancer, as well as the negative perceptions of screening
tests that involve genital organs, have been identified as
problems in the demand side (Angkasuwapala quoted in
[12]). Impediments on the supply side also play an
important role. Firstly, policy direction concerning the
introduction of Pap smears and VIA is unclear and
there is poor collaboration between the two responsible
departments [11]. As a consequence, health providers
are confused and reluctant to choose one to implement.
Secondly, a reliable and regularly updated information
system related to cervical cancer screening and treat-
ment is not in place. This information is necessary for
program monitoring and evaluation, at both the national
and local levels. Thirdly, poor attitudes towards VIA
among medical doctors has resulted in their resistance
to the use of this approach. VIA is perceived as a ‘low-
grade’ approach, suitable for only the least-developed
countries. Others argue that this intervention is not an
appropriate alternative to Pap smears since evidence
from randomised control studies indicates that the test
is inaccurate and not of good quality [13].
Yet surprisingly, in mid 2008, the MoPH decided to
scale up the coverage of its Pap smear and VIA services
to meet an ambitious target. The main objective of this
study was to assess the policy processes and related fac-
tors that drove this radical policy shift and shaped the
implementation of such an unexpected initiative, as well
as to examine the level of success of the policy.
Conceptual starting points and research methods
The question of why policymakers pay attention to par-
ticular problematic issues, which in turn increases the
chance for major policy shifts, has been addressed in
many agenda-setting studies. Kingdon [14] suggests that
a window of opportunity for policy innovation opens
when the three independent streams of problem, solu-
tion and politics meet: a social phenomenon is recog-
nised as a problematic issue, an appropriate solution to
tackle such a problem is available, and there is sufficient
political development that allows actors with new ideas
to be involved in decision-making. Moreover, following
Kingdon, the coupling of the three elements is facilitated
by policy entrepreneurs and focusing events. The former
are actors who put strong, persistent efforts into pro-
moting certain policies, while the latter are rare and
prominent events, such as natural disasters, accidental
tragedies, and scientific discovery that enhance the per-
ceived need for government action among policymakers.
This study focuses on the development of cervical
cancer control policy in Thailand during the period Jan-
uary 2006 to July 2009. The study sought to understand
the policy processes that led to the formulation of a
plan for the rapid extension of cervical cancer screening
services. It did this by exploring the processes of pro-
blem recognition, policy identification, and political
mobilization. This analysis also examines the existence
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raising the issue not only of cervical cancer but also of
its screening tests onto the Health Ministry policy
agenda. Despite the fact that this paper analyses the
introduction of a campaign with a very short lifespan,
i.e. only three months, the authors consider this govern-
ment action to be an initial effort to expand cervical
cancer screening coverage. Such expansion could have
been achieved if responsible officials had kept up the
momentum of implementation beyond this initial per-
iod. Therefore, the scaling up notion, in the sense of
expanding coverage of a priority health intervention
[15], together with the way in which the scaling up pro-
cess is managed [16] is employed as a framework for
discussing the policy processes.
The study applied qualitative approaches, including
documentary review, in-depth interviews, and personal
communication and observation derived from the
researchers’ direct participation in the policy-related
events. The documents reviewed comprise memoranda,
meeting minutes, information sheets, research reports, let-
ters and other documents produced by government agen-
cies, private businesses, the media and non-governmental
organizations (NGOs). The information obtained from
these documents included the features of the cervical can-
cer control programs, including the performance and
obstacles to the program, the cost-effectiveness of screen-
ing tests for cervical cancer and HPV vaccination in Thai-
land and other countries, the official positions of different
organizations towards the scaling up of the screening tests
and the introduction of the HPV vaccine. The information
also included the evolution of the policy of expanding
cervical cancer screening services in 2008.
In-depth interviews were undertaken with five key sta-
keholders identified through document reviews and the
use of the snowball technique. The interviewees
included two senior officials involved in cancer screen-
ing programs, a senior administrator in the National
Cancer Institute, a senior manager of the UC scheme,
and a researcher in the Health Intervention and Tech-
nology Assessment Program (HITAP) who was involved
in conducting and disseminating a study on cervical
cancer prevention. An interview guide was developed
based on the responsibilities and potential role of each
interviewee in cervical cancer control. The information
sought in the interviews comprised the major drivers of
the policy to scale up the screening tests for cervical
cancer, and the characteristics of the policy formulation
and implementation processes including obstacles and
interaction between key interests in different stages of
the policy. A content analysis approach was employed
to identify concepts and elements concerning the three
streams of problem, policy and politics, and their inte-
gration as suggested in Kingdon’s [14] model, as well as
to allow for newly-emerging themes. The analysis was
verified by triangulation across the different sources.
Working in HITAP, a semi-autonomous research
institute under the Health Ministry, all researchers in
this study were involved in processes linked to the pol-
icy under investigation. They conducted a series of stu-
dies concerning preventive measures for cervical cancer
and covered several different aspects such as economic
evaluation, program performance, preferences and per-
ceptions towards particular policy options of key stake-
holders, and the effects of marketing strategies to
encourage immunization against HPV in Thailand.
Some researchers also participated in research dissemi-
nation and policy consultations. Such experiences
allowed the researchers to gather insights into the policy
development processes. At the same time, however, this
close participation in the policy may challenge the
researchers’ impartiality. To reduce potential bias, a
meeting of policymakers, health officials, and representa-
tives from the vaccine companies and NGOs was con-
vened in early September 2009 to discuss and verify the
preliminary research findings. The workshop confirmed
the main findings of this study, and also provided addi-
tional information that helped to explain some elements
in the policy under investigation.
Results
The development of cervical cancer prevention policy in
Thailand
The effort to control cervical cancer in Thailand can be
traced back to the 1960s when the Pap smear test was
introduced as a clinical examination for individuals
who attended hospital services such as family planning,
ante- and post-natal clinics, and treatment for sexually-
transmitted infections (Table 1) [9]. No data are avail-
able on the coverage of Pap smear tests in this period,
since the service did not aim for disease screening at the
population level. It is believed, however, that the num-
ber of women screened was very limited. It was not
until 2002 that the MoPH’s Department of Medical Ser-
vices established a cytology-based screening program for
the entire female population aged 35 to 60 years. In
2000 the provision of VIA and cryotherapy, for screening
purposes, began as a demonstration project in a small
number of provinces with support from the JHPIEGO
Corporation, the Royal Thai College of Obstetricians and
Gynecologists (RTCOG) and the MoPH’s Department of
Health [17]. From 2004 the two screening approaches
were included in the benefit package for disease preven-
tion supported by the UC scheme.
The discovery of the association between HPV infec-
tion and cervical cancer in the 1980s [2] led to the
development of a prophylactic vaccine which was
expected to be a major breakthrough in reducing the
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HPV-related diseases. In 2006, the first vaccine against
this virus was approved by the United States Food and
Drug Administration [18]. One year later, two HPV vac-
cine products were licensed in Thailand. However, the
MoPH took the position that it would not provide the
HPV vaccine in the national vaccination program, but
instead recommended that the target population seek
regular cervical cancer screening tests to prevent the
disease. The Director General of the Department of Dis-
ease Control (quoted in [19]), revealed that the Ministry
would not consider putting the HPV vaccination into its
program even though it could prevent up to 70% of
infections. The justification for this policy was that the
vaccine price of 14,000-21,000 baht (400-600 USD) per
3-dose course was unaffordable within the government
budget, and that the conventional methods of cervical
cancer prevention were effective. As of April 2009 the
vaccine had still not been included in the national
immunisation programme nor had it been covered
under public health benefit plans. It was, however, avail-
able in the private sector for those who could afford to
pay out of pocket.
Although the MoPH considered screening tests as the
most appropriate and practical strategy for cervical can-
cer control, it was not until 15
th August 2008 that it
declared a policy to strengthen its screening services.
The Health Minister announced at a press conference
that the Ministry would scale up its Pap smear and VIA
testing services to reach one million women between 35
and 60 years of age, irrespective of their health benefit
or insurance plans [20]. This campaign would be carried
out during the 116-day period from 12
th August to 5
th
December 2008, known in Thailand as Mother’sD a y
and Father’s Day respectively. Such an announcement
caught the policy audience, especially health officials
and professionals, by surprise since there had been no
previous warning of this radical policy shift. In particu-
lar, there was no consultation with health officials and
experts in the design of the scaling up initiative. More-
over, the target of the campaign was considered ambi-
tious given that the screening program had only had an
average annual uptake of 790,000 clients in previous
years [21].
The following sections of this paper discuss how cervi-
cal cancer – a disease which had been neglected for
decades – was recognised by the Health Minister as a
crucial problem that required immediate action, and
why scaling up Pap smear and VIA programs, rather
than introducing the newly-emerging technology of
HPV vaccine, were adopted as the policy interventions
to reduce the disease morbidity and mortality in
Thailand.
Promotion of HPV vaccination: A reminder of neglected
screening programs for cervical cancer
It was not long before the shift in Thailand’s cervical
cancer screening program that the success in the
research and development of an HPV vaccine was publi-
cized globally. Promotion campaigns for HPV vaccina-
tion as an effective intervention to curb cervical cancer
were implemented not only by the vaccine companies
but also by international health agencies and NGOs.
The common issues proposed by these organizations
Table 1 Chronological events related to cervical cancer prevention policy in Thailand
Date Important event
1960s Introduction of Pap smear as clinical examination in women who attended particular services in hospitals
2000 Instigation of VIA program as a pilot project for screening purposes
2002 Pap smear offered, as screening test, to entire female population between 35 and 60 years old
2004 Cervical cancer screening tests covered by national Universal Coverage scheme
2006 ■ Launch of first HPV vaccine in the United States of America
■ Distribution of first WHO policy and technical document concerning HPV vaccination to policymakers and health workers
2007 ■ Two HPV vaccine products licensed for use in Thailand
■ Consultations on cervical cancer control and HPV vaccination among WHO Member States in 6 regions including the South-
east Asia and Western Pacific regional meeting in Thailand in April
■ A study to identify an optimal strategy for cervical cancer prevention in Thailand was conducted by 2 research institutes under
the MoPH, namely IHPP and HITAP. The preliminary results were disseminated in December
2008 ■ The GAVI Alliance announced it would consider future support of new and underused vaccines to fight deadly disease in
developing countries which included cervical cancer
■ A Declaration made at the World Cancer Congress in Geneva in August called for action to ensure that HPV vaccines and
other effective strategies to prevent cancer-causing infection were made widely available
■ Changes in Thailand’s Prime Minister in January, September and December and many cabinet reshuffles
■ IHPP-HITAP study report launched in August
■ From August to December, the MoPH introduced a campaign to extend the coverage of its cervical cancer screening service:
the ‘116-Day initiative’
2009 ■ Price for the two HPV vaccine products were reduced by the vaccine companies in February and April
Note: GAVI Alliance stands for Global Alliance for Vaccines and Immunization; IHPP for International Health Policy Program; and HITAP for Health Intervention and
Technology Assessment Program.
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program management in poor settings, financing con-
cerns, increasing awareness of the vaccine availability
and potential benefits of the vaccine [22,23]. Inevitably,
however, deliberations around the new technology also
touched upon the existing alternatives and the burden
of the disease itself. In particular, the affordability and
cost-effectiveness of HPV vaccination in comparison to
those of Pap smears and VIA were the centre of debate,
as the two vaccine products were sold at very high
prices [24,25].
The World Health Organization (WHO) played a sig-
nificant role in increasing the awareness of cervical can-
cer prevention approaches through several activities
carried out by its Headquarters and regional offices dur-
ing the years 2006-2008. These included the distribution
of policy and technical information to policymakers and
health professionals through a set of documents
[1,26,27]. Consultations concerning HPV vaccines were
held in all WHO regions. In April 2007 a meeting of
Member States in the Western Pacific and South-East
Asia regions was convened to discuss the current status
of cervical cancer control programs in countries, the
means to strengthen these services, whether and how
HPV vaccination could be introduced, and the potential
roles of WHO and other health and development part-
ners [28]. Owing to the high costs of the vaccination,
policymakers and experts from the two regions, includ-
ing the Thai delegation, realized the need to ‘do the best
that they can afford to do’ by strengthening the efforts
for cervical cancer screening.
After the launch of the HPV vaccine on the global
m a r k e t ,t h ev a c c i n ei n d u s t r yb e c a m ea na c t i v ep l a y e ri n
cervical cancer control policy debates. As key informants
revealed in interviews in May 2009, when the vaccine
became available in Thailand, representatives of the two
vaccine producers contacted senior health officials in
the Health Ministry and public health insurance office
as well as experts and clinicians, with the aim of pursu-
ing publicly-financed HPV vaccination as part of the
national immunization program and the UC scheme.
Moreover, the industry convened conferences and aca-
demic fora, occasionally in collaboration with NGOs, to
discuss the feasibility of and potential impediments to
HPV vaccination [29,30]. In most of the meetings, the
vaccine price and its impact on the government budget
were highlighted by health officials and policy research-
ers. Also, the strengths and weaknesses of cervical can-
cer screening services were occasionally mentioned by
both those opposing and those supporting a publicly-
subsidised HPV vaccination program. In early 2009, by
which time it was clear that one of the government’s
main concerns was the unaffordable cost of the vaccine,
the two vaccine producers offered significant price
reductions in their products. Nevertheless, by April
2009, the pricing strategy had still not succeeded in
encouraging national authorities to introduce mass
immunization against HPV.
The introduction of HPV vaccine and related discus-
sions and debates can be regarded as focusing events for
cervical cancer screening services. As Kingdon (1984)
argues, focusing events may contribute to a policy
change by triggering sufficient public demand for a pol-
i c yi n n o v a t i o nt h a ti tc a n n o tb er e s i s t e db yt h ea u t h o r i -
ties. An early study in Australia illustrated the critical
role of public opinion and political mobilization in
encouraging a government decision to adopt publicly-
funded HPV vaccination [31]. Although in Thailand
there was no strong public movement on the issue,
debates about the HPV vaccine certainly focused atten-
tion on cervical cancer as policy problem amongst pol-
icy makers.
The role of policy entrepreneurs
Thai experts held different positions on whether to
introduce the HPV vaccine nationwide. Some clinicians
argued that the vaccine, when introduced alongside Pap
smears, is the most effective means to prevent cervical
cancer and other HPV-related diseases. Occasionally,
these clinical experts expressed their support of the vac-
cination in conferences and public education events
convened by NGOs and vaccine companies. However, a
group of obstetricians and gynaecologists emphasized
the need to enhance screening test provision since the
cost of HPV vaccination was unaffordable [10]. In addi-
tion, the RTCOG and oncologists associations issued a
joint statement in July 2008 titled ‘HPV vaccines and
cervical cancer prevention’ [ 3 2 ]a i m e da tp r o v i d i n gt h e
public with guidance for encouraging the rational use of
HPV vaccines.
I nt h ef a c eo ft h e s ed i f f e r e n tpositions, it was policy
researchers from two institutes under the MoPH who
had a crucial role in informing policy decisions with evi-
dence. From early 2007 to 2008, the IHPP and HITAP, in
collaboration with experts from the RTCOG and other
organisations, carried out a project: ‘Research for the
development of an optimal policy strategy for prevention
and control of cervical cancer in Thailand’ [11], with
financial support from the World Bank’s Population and
Reproductive Health Capacity Building Program. The
study provided insights into the inadequate performance
of cervical cancer screening services and proposed an
optimal strategy to control the disease. The findings illu-
strated substantial room for improvement in the coverage
and quality of the national cervical cancer prevention
program. Furthermore, the study suggested that screen-
ing tests are cost-saving, in comparison to treatment of
cervical cancer, and that the most cost-effective option to
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smears, by providing VIA every 5 years to women 30 to
45 years of age, and Pap smears every 5 years to those
between 46 and 60 years old. Importantly, HPV vaccina-
tion was found to be cost-ineffective owing to the very
high price of the vaccine.
In December 2007, the preliminary results of two ele-
ments of this study, the performance assessment of the
national cervical cancer screening program and the eco-
nomic evaluation of policy options for the prevention
and control of cervical cancer in Thailand, were dis-
cussed amongst representatives of MoPH departments,
the NHSO, the RTCOG and the vaccine companies. It
was the first time these stakeholders obtained compre-
hensive information concerning cervical cancer control
strategies. One of the researchers in this project pointed
out in an interview in early 2009 that she and her col-
leagues were often invited to give presentations on the
study results at policy fora including those organised by
the Department of Health’s Reproductive Health Divi-
sion, the Subcommittee for the Development of Benefits
and Service System under the UC, and the NHSO’s
Working Group on the Development of Cervical Cancer
Screening System. Thus, policymakers who were respon-
sible for priority setting and resource allocation in the
health sector were exposed to information on the per-
formance of the existing cervical cancer prevention ser-
vices and also the economic aspects of screening tests
and the new technology, the HPV vaccine. Furthermore,
HITAP disseminated the study findings and information
concerning the rational use of the HPV vaccination to
the public through different channels such as a public
forum in August 2008 and television programmes.
The broader political context
After a military coup in 2006, Thai politics were in a
chaotic and unstable state. A series of street demonstra-
tions were held seeking to achieve the removal of the
administration, which had been elected in January 2008,
and calling for a new election. However, the coalition
government did not dissolve the parliament, but rather
appointed new Prime Ministers and Cabinets. During
2 0 0 8t h e r ew e r e4p r i m em i n i s t e r sa n dm a n yc a b i n e t
reshuffles. In response to the increase in social disorder
in mid-2008, several public programs were introduced
with the aim of gaining public support and extending
the political life of Cabinet members. The one hundred
and sixteen day period from 12
th August to 5
th Decem-
ber was selected by the Cabinet as the timeframe for
implementing populist policies by all government minis-
tries. The MoPH’s 116-Day campaign focussed on the
extension of cervical cancer screening services. A senior
advisor in the MoPH who often worked closely with the
Health Minister noted that, ‘I informed the Minister that
if he pursued this policy, he would win the heart of all
women. Then, he agreed and gave me the green light.’ In
the same vein, another senior official argued in an inter-
view in 2009 that, ‘I discussed with the Minister and
informed him that the screening program including
essential infrastructure for the service scaling up already
existed, but a clear policy was needed. If the Minister
pushed it, it could be successful and he would gain social
credit without any significant additional investment.’
Prior to the political crisis of mid-2008 the Health
Minister might neither have recognised the launch of
the HPV vaccine on the global and domestic market,
nor obtained information on the vaccine, or even exist-
ing cervical cancer control programs. However, such
developments posed an important question to health
officials, experts and researchers: was HPV appropriate
and feasible in the Thai setting? The IHPP-HITAP
study was, therefore, timely and addressed the demand
for evidence-based recommendations. In interviews,
senior health officials argued that the study findings
were not surprising and confirmed their belief that HPV
vaccination was not suitable in Thailand unless the vac-
cine price fell significantly. As these key informants indi-
cated, the recommendation to strengthen the national
screening programs was largely in line with what they
had already recognised as a priority action, even though
some of them felt that the combined introduction of
VIA and sequential Pap smears was not necessary.
Interview respondents asserted that dissemination of
the IHPP-HITAP study was influential in prompting
them to call for the improvement of the national cervi-
cal cancer screening services. As a high ranking official
in the MoPH pointed out in an interview, ‘If you ask
whether my participation in the seminar prompted me
to raise this issue to the Health Minister, I can say that
it played a part. It was the IHPP-HITAP study that
made me increasingly interested in the issues of HPV
vaccination and cervical cancer screening.’ A similar
a r g u m e n tw a sm a d eb yt h eD i r e c t o rG e n e r a lo ft h e
Department of Health who noted that he recognised the
results of the economic evaluation and felt the need to
convey the information to the Health Minister, as he
w a sa m o n gt h ef e wp e r s o n sw h oc o u l dp l a yal e a d i n g
role in improving the fragmented screening program. As
these officials put it, they made the proposal to this key
policymaker because they were aware that the cabinet
was keen to introduce any programs that offer benefits
to the general population, and felt that strengthening
the national cervical cancer screening services would
meet this political demand.
What was the scaling up process?
In interviews in 2009, two senior health officials noted
that they proposed the scaling-up of cervical cancer
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Unexpectedly, in a press conference on 15
th August, the
Health Minister announced the 116-Day campaign. This
suggests that the policy was adopted and formulated in
a very short period of time. As highlighted by the
respective program managers, neither the operational
plan, nor the mechanisms for monitoring and evaluation
of the service extension, were put in place. Moreover,
no participation from stakeholders such as clinical
experts and health providers could be observed during
the policy formulation and implementation process.
Financial resources from the MoPH and the NHSO
were, however, allocated to public information activities.
An administrator at the National Cancer Institute –
the main agency responsible for the 116-Day initiative –
pointed out that although this policy aimed to
strengthen screening services for cervical cancer, there
was no guidance regarding revision of the operating
procedures for screening practices at health centres and
community hospitals where the majority of the tests
were provided. In addition, no solutions to counter the
already known obstacles to the provision of screening
services were identified; these included the inadequate
number of cytologists, mistrust in the VIA approach
among physicians, problems related to the referral sys-
tem between primary care settings and higher-level
institutions. During the implementation phase of this
campaign sporadic media coverage and public-informa-
tion events could be observed. A high-ranking official
who claimed a role in raising the cervical cancer screen-
ing issue with the Health Minister revealed that this
initiative was not introduced in the way he had
expected: ‘I do not expect to see the policy for expansion
of cervical cancer screening being implemented like this,
Iw i s h e dt os e ei ti m p l e m e n t e di nam o r er i g o r o u sa n d
sustainable way.’
Evidence indicating the achievements of the campaign
is provided by the number of clients served. On National
Cancer Day, 9
th December 2008, the Director of the
National Cancer Institute reported through the public
media that 82,700 women were screened for cervical can-
cer during the 116-day period [33]. This figure was only
slightly higher than the number of screening tests per-
formed during the same period in the previous year.
Although there was no formal evaluation of the 116-Day
initiative, key informants in this study shared a common
view that the policy scale up was unsuccessful. They
identified the barriers to scaling up as: lack of policy
clarity on the introduction of VIA and its harmonisation
with the long existing Pap smear program, inadequate
preparation for the 116-Day campaign, and a low aware-
ness of the need for the service in the target population.
It is noteworthy that in conjunction with the 116-Day
campaign, there was also an initiative to strengthen the
screening program for cervical cancer in Thailand.
Despite being mandated as a health care purchaser, in
October 2008 the NHSO appointed a task group to the
Development of the Cervical Cancer Screening Service
System. This group comprised officials responsible for
the Disease Prevention andH e a l t hP r o m o t i o nF u n d ,
representatives from the Department of Health, the
Department of Medical Services and the RTCOG, and
researchers who were involved in the World Bank
funded study. In a meeting on 20
th November, 2008 the
task group endorsed the use of either Pap smears or
VIA for cervical cancer screening and made it clear that
either of the tests could be reimbursed under the UC
plan. This meant health providers could choose the
approach they considered to be the most appropriate to
their setting. For instance, VIA would be employed in
those facilities unable to provide the Pap smear service
and proper treatment of abnormal cells. Recognizing the
inadequate performance of the screening test service,
the task group also called for proposals from interested
health agencies to extend the service. This was to meet
the target of screening 80% of women aged 35 to 60
years old within the next five years. However, this effort
had only made limited progress when the 116-Day cam-
paign ended in December of the same year.
Discussion
This Thai case study illustrates a number of critical fac-
tors in the problem, policy and political streams that
encouraged the rise of cervical cancer screening onto
the governmental agenda – the process that led to
authoritative decisions ande v e n t u a l l y ,t h e1 1 6 - D a y
initiative in 2008. In line with Kingdon’s[ 1 4 ]a g e n d a
s e t t i n gm o d e l ,w er e c o g n i s et h ed i s c o v e r ya n dd i s t r i b u -
tion of the HPV vaccine as a focusing event – an
obvious, sudden, relatively uncommon event that high-
lights a problematic issue and/or a solution to which
policy authorities and the public pay attention. Without
this discovery and its distribution, policymakers and
other key policy stakeholders in Thailand, and around
the world, might not have recognised the cervical cancer
burden and available prevention measures. In particular,
since the newly-introduced technology was unaffordable
f o rp o o rc o u n t r i e s ,s c r e e n i ng tests were revisited and
discussed by international and national health organiza-
tions, as effective alternative means of curbing the dis-
ease. Health authorities and experts in most settings did
not recommend HPV vaccination as a substitute for
screening services, but as a complementary measure.
Policy researchers in the Health Ministry played a signif-
icant role both in generating evidence concerning the
cost-effectiveness of cervical cancer screening services and
HPV vaccination, and in disseminating the research find-
ings to policymakers and administrators in responsible
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enabled the coming together of the problem and policy
streams. These actions did this by getting the leaders of
national health authorities to recognize the magnitude of
cervical cancer burdens and become aware of the room
for improvement in the screening program. All this hap-
pened while the country was faced with a political crisis in
which members of the Cabinet needed to present the pub-
lic with their successful policies in order to gain the popu-
larity that would help secure their government’s position.
It is noteworthy that despite catching the attention of
researchers, health officials and politicians, the issue of
cervical cancer and screening tests did not reach the
attention of the general public, which means that most
Thai people, including those targeted by the services, were
not involved in the policy shift. Indeed, the analysis also
illustrates that the policy shift was influenced by a limited
number of actors based solely in the MoPH, with other
interests, such as the media and NGOs, playing no role.
Although agenda setting generally involves the rise of
interest in a policy problem and, in some instances, its
corresponding solutions, this process does not guarantee
success in subsequent stages of policy formulation and
implementation [34,35]. The political rhetoric and top
down instructions associated with the 116-Day initiative
were inadequate to achieve the extended target for cervi-
cal cancer screening. Following Hanson et al [36], the
scaling up of essential health services requires several ele-
ments, some of which did not exist for this initiative.
These included, in particular, those defined as strategic
management factors such as involvement and collabora-
tion between key actors in decision making and imple-
mentation units, as well as decentralized mechanisms for
policy formulation, planning and administration. Hanson
et al. also argue that the constraints to extending public
health program coverage may involve contextual factors
such as political instability and weak governance. Key
informants in this study certainly maintained that the
shortfalls in the 116-Day initiative resulted mainly from
the chaotic political situation as this did not allow suffi-
cient preparation and engagement between the central
departments and local service providers.
The findings of this analysis are in line with existing
literature which highlights the crucial role of political
factors, including policy elites, not only in facilitating
and impeding policy shifts but also in guiding the suc-
cess or failure of the innovations in particular settings
[37,38]. An analysis of health financing policy in South
Africa and Zambia demonstrates, meanwhile, the unde-
sirable consequences of rapid policy changes under-
pinned by political drivers, as they may fail to carry
forward through policy formulation and implementation
[39]. These African experiences also emphasize the gen-
eral importance of management strategies in successfully
translating policy prescriptions into action [16]. These
include the needs for relevant technical capacity, effec-
tive design of proposals and clear communication of
policy changes. In the scaling-up of cervical cancer
screening services in Thailand, although the capacity to
conduct technical analysis existed in the Health Minis-
try, research institutes and even in peripheral health
facilities, this expertise was not consulted in devising the
ambitious campaign.
An important limitation of this research is that it does
not explore the process of scaling-up cervical cancer
screening at the peripheral level. Therefore, the real pro-
blems faced by health providers in implementing the
MoPH’s 116-Day campaign to strengthen the cervical can-
cer screening services have not been identified. It is also
worth noting that official statistics indicate little extension
of services during the program implementation period.
However, given that a top-down model of policy imple-
mentation was applied, it is not surprising that this initia-
tive was not successful. An extraordinarily short period
was available to develop this national-scale campaign pro-
tocol and lessons learned from past experience related to
the screening program were not drawn on as inputs in for-
mulation of the policy. Without action to counter the
already known obstacles to service provision, it was clearly
difficult to meet the campaign’s ambitious target.
Fortunately, though, the current development of
Thailand’s cervical cancer screening program indicates
subsequent improvement regarding its coverage, effec-
tiveness and efficiency. The continuing advocacy for
HPV vaccination provides a conducive context for the
government to strengthen the screening service provi-
sion as it is the only affordable choice currently avail-
able. Furthermore, from early 2009 the MoPH’s
Department of Health, in collaboration with other orga-
nizations, including the Department of Medical Services,
has been introducing a pilot program which offers cervi-
cal cancer screening, with the operational strategy as
recommended by the IHPP-HITAP study, in a number
of provinces. Meanwhile, the NHSO and the MoPH are
implementing a plan to enhance existing databases and
reporting systems related to cervical cancer control. All
of these actions may, to some extent, help to ensure bet-
ter performance of the screening program which will be
gradually scaled up in the future.
It is often argued that the main obstacles to health
system development in resource-limited settings are
inadequate financial and human resources, as well as
the lack of relevant and reliable evidence to guide
proper policy decisions. This Thai case study shows that
even though scientific evidence concerning the safety,
efficacy, effectiveness and value for money of policy
options for prevention and control of cervical cancer
were available, with political will, adequate financial
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up of the screening service in Thailand did not achieve
its promise in its explicit phase of implementation. This
suggests the need for policy managers to have a better
understanding of the processes of policy development,
including insight into the roles of stakeholders, their
interests, and interactions with the health system con-
text. However, analysis of health policy is rarely recog-
nized and applied in developing countries’ academic
institutes and health administrative authorities [40].
Conclusions
In conclusion, this study provides an illustration of the
effort to strengthen cervical cancer prevention programs
in a middle-income country, with relatively strong
health care delivery and financing systems. This policy
innovation took place within the Health Ministry just
after the HPV vaccine was launched onto the market
and advocated for by interest groups including interna-
tional organizations, the vaccine industry and private
health providers. However, the scaling-up of the screen-
ing services did not reach its ambitious target inside its
own timeframes as it was largely driven by political fac-
tors and was not well devised.
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